专家建议在炎症性肠病临床试验中标准化转录组分析
Bryan Linggi1, Salas Azucena2, Boyd Steere3
1Alimentiv Inc., London, Ontario, Canada.
Journal of Crohn's & colitis
|April 28, 2025
概括
在炎症性肠病 (IBD) 临床试验中标准化转录组研究至关重要. 这项研究制定了专家建议,以解决方法异质性,并改善IBD转录组学数据的解释.
科学领域:
- 基因组学和分子生物学
- 胃肠病学 胃肠病学
- 翻译研究是翻译研究.
背景情况:
- 炎症性肠病 (IBD) 研究中的转录数据存在重大方法和报告不一致.
- 这种异质性阻碍了IBD转录组研究结果的解释和概括性.
- 标准化是必要的,以提高临床试验中转录组数据的价值.
研究的目的:
- 为在炎症性肠病 (IBD) 临床试验中标准化转录基因研究制定专家建议.
- 解决和克服IBD转录组研究中现有的方法差异.
- 促进将标准化转录基因研究纳入临床开发.
主要方法:
- 一项系统性审查确定了使用全球RNA测定平台的IBD临床试验中37份转录组分析报告.
- 经过修改的R&D/UCLA适当性方法过程和专家调查被用于制定和评价建议.
- 16名IBD转化研究人员和胃肠科医生参加了两轮的适当性评级.
主要成果:
- 系统性审查发现了研究设计,方法和报告中的大量异质性.
- 专家小组在305个陈述中评价了75%的陈述,认为这些陈述适合在IBD中标准化转录基因研究.
- 为样本大小,活检处理和数据分析/报告提出了建议.
结论:
- 方法上的异质性仍然是IBD转录基因研究的挑战.
- 专家驱动的建议旨在在IBD临床试验中标准化转录组研究.
- 实施这些建议将改善数据质量和临床实用性.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
246
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
246
Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
100
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
100
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
105
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
105
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
87
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
87
Inflammatory Bowel Disease I: Ulcerative Colitis
98
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
98


